Aura Biosciences宣布Bel-SAR治疗早期脉络膜黑色素瘤的3期Compass试验完成患者入组

美股速递06-01

Aura Biosciences, Inc. 近日宣布，其针对早期脉络膜黑色素瘤的在研疗法Bel-SAR，其关键性3期临床试验“Compass”已完成全部患者入组工作。这一里程碑标志着该创新疗法在临床开发道路上迈出了至关重要的一步，为后续的数据收集与分析奠定了坚实基础。脉络膜黑色素瘤是一种罕见但严重的眼内恶性肿瘤，Bel-SAR作为一种新型靶向疗法，旨在为患者提供一种潜在的有效治疗选择。此次试验的顺利推进，有望为满足这一未竟的医疗需求带来新的希望。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1137059152?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-01 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137059152","market":"us","top_or_hot":-1,"title":"Aura Biosciences宣布Bel-SAR治疗早期脉络膜黑色素瘤的3期Compass试验完成患者入组","media":"美股速递","content":"<p>Aura Biosciences, Inc. 近日宣布，其针对早期脉络膜黑色素瘤的在研疗法Bel-SAR，其关键性3期临床试验“Compass”已完成全部患者入组工作。这一里程碑标志着该创新疗法在临床开发道路上迈出了至关重要的一步，为后续的数据收集与分析奠定了坚实基础。脉络膜黑色素瘤是一种罕见但严重的眼内恶性肿瘤，Bel-SAR作为一种新型靶向疗法，旨在为患者提供一种潜在的有效治疗选择。此次试验的顺利推进，有望为满足这一未竟的医疗需求带来新的希望。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aura Biosciences宣布Bel-SAR治疗早期脉络膜黑色素瘤的3期Compass试验完成患者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAura Biosciences宣布Bel-SAR治疗早期脉络膜黑色素瘤的3期Compass试验完成患者入组\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-01 20:00 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aura Biosciences, Inc. 近日宣布，其针对早期脉络膜黑色素瘤的在研疗法Bel-SAR，其关键性3期临床试验“Compass”已完成全部患者入组工作。这一里程碑标志着该创新疗法在临床开发道路上迈出了至关重要的一步，为后续的数据收集与分析奠定了坚实基础。脉络膜黑色素瘤是一种罕见但严重的眼内恶性肿瘤，Bel-SAR作为一种新型靶向疗法，旨在为患者提供一种潜在的有效治疗选择。此次试验的...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AURA","symbol_name":"Aura Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1137059152","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137059152","pubTimestamp":1780315253,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Aura Biosciences, Inc. 近日宣布，其针对早期脉络膜黑色素瘤的在研疗法Bel-SAR，其关键性3期临床试验“Compass”已完成全部患者入组工作。这一里程碑标志着该创新疗法在临床开发道路上迈出了至关重要的一步，为后续的数据收集与分析奠定了坚实基础。脉络膜黑色素瘤是一种罕见但严重的眼内恶性肿瘤，Bel-SAR作为一种新型靶向疗法，旨在为患者提供一种潜在的有效治疗选择。此次试验的顺利推进，有望为满足这一未竟的医疗需求带来新的希望。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AURA":"Aura Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"Aura Biosciences Announces Completion of Patient Enrollment in Phase 3 Compass Trial of Bel-SAR for Early Choroidal Melanoma","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AURA":1},"content_text":"Aura Biosciences, Inc. 近日宣布，其针对早期脉络膜黑色素瘤的在研疗法Bel-SAR，其关键性3期临床试验“Compass”已完成全部患者入组工作。这一里程碑标志着该创新疗法在临床开发道路上迈出了至关重要的一步，为后续的数据收集与分析奠定了坚实基础。脉络膜黑色素瘤是一种罕见但严重的眼内恶性肿瘤，Bel-SAR作为一种新型靶向疗法，旨在为患者提供一种潜在的有效治疗选择。此次试验的顺利推进，有望为满足这一未竟的医疗需求带来新的希望。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137059152","isCrawlerRequest":true}